Navigation Links
Signature Therapeutics, Inc., Presents Four Scientific Posters Today at PAINWeek 2013 Meeting
Date:9/5/2013

PALO ALTO, Calif., Sept. 5, 2013 /PRNewswire/ -- Signature Therapeutics, Inc., today presented four scientific posters at the PAINWeek 2013 national conference in Las Vegas.  The posters illustrate the company's (i) trypsin-labile, immediate- and extended-release opioid prodrugs that release the parent opioid following oral administration; (ii) results of extended-release prodrugs oxycodone and hydromorphone withstanding tampering and abuse using standard crushing and extracting techniques; and (iii) First-in-man study findings of its trypsin-liable extended-release hydromorphone prodrug.

(Logo:  http://photos.prnewswire.com/prnh/20130729/SF54809LOGO)

Every year in the United States prescription opioid abuse is responsible for tens of thousands of deaths and tens of billions of dollars in increased health care costs.  Wes Sterman, President and CEO of Signature Therapeutics, commented, "We believe that our prodrug technology approach creating abuse-deterrent opioid drugs has the potential to greatly impact the public health crisis of prescription drug abuse."

About The Opioid Abuse Challenge

The abuse and misuse of prescription opioid drugs has reached epidemic proportions in the United States. Despite efforts to develop opioid drug formulations that are resistant to tampering, abusers will soon match the advances in pill/tablet formulation technology with new ways to abuse these drugs.  Typical methods of abuse of prescription opioid drugs include inhaling or injecting crushed pills or chewing intact pills.  Current efforts to thwart these modes of abuse, involving improved tablet-formulation technology to make tablets harder to crush and the opioid drug harder to remove from the tablet, provide some increased level of abuse-resistance.  However, Signature Therapeutics' prodrug technology involves creating new molecules that provide very high levels of abuse-resistance based upon the design of the molecules themselves.

About Signature Therapeutics

Signature Therapeutics, Inc. is a development-stage biopharmaceutical company located in Palo Alto, California.  The Company focuses on the discovery and development of a portfolio of novel chemical entities for the potential treatment of neurological disorders.

Signature Therapeutics Contact:

Carey DeRafael

email: cderafael@signaturerx.com
phone: 650-331-4006
website: http://www.signaturerx.com



'/>"/>
SOURCE Signature Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Senator Shares Insight on Florida Physician Dispensing Legislation as First Guest of Progressive Medicals New SignatureSeries
2. Signature Therapeutics Receives BrIDGs Award to Advance Its Abuse-Deterrent Oxycodone, PF614
3. CLAAD Lauds Signature Therapeutics R&D Efforts To Reduce Prescription Drug Abuse
4. Wacoms New DTU-1031 Provides Paperless Electronic Signature Solution for Businesses
5. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
6. PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
7. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
8. Aratana Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
9. Autoinjectors to 2018 Devices, Therapeutics, Markets, Strategies and Prospect
10. ADVENTRX Completes Name Change To "Mast Therapeutics, Inc."; New Ticker Symbol: "MSTX"
11. Autoinjectors to 2018 - Devices, Therapeutics, Markets, Strategies and Prospects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... -- Montoya Love is recognized by Continental Who,s Who as ... is the Regulatory Systems Operations Manager with Becton ... Manufacturing and selling a broad range of medical ... institutions, clinical laboratories and life science researchers with the ... An ...
(Date:2/4/2016)...  Omnicell, Inc. (NASDAQ: OMCL ), a leading provider ... today announced results for its fiscal year and fourth ... --> GAAP results: Revenue for the fourth ... or 4.1% from the third quarter of 2015, and ... of 2014. Revenue for the year ended December 31, 2015 ...
(Date:2/4/2016)... (NASDAQ:  AMRI) today announced that Anthony J. Maddaluna , ... Global Supply, has been elected to the AMRI Board of ... Company announced that Mr. Gabe Leung , a director ... from the AMRI Board of Directors in order to devote ... William S. Marth , President and CEO. "We ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... 2016 , ... Successful recruitment and retention efforts, new collaborations ... have all marked the last 12 months at Roswell Park Cancer Institute (RPCI). ... oldest cancer center, Candace S. Johnson, PhD, outlined the many accomplishments of her ...
(Date:2/5/2016)... ... 2016 , ... Looking for a last-minute Valentine’s Day gift for the special ... Foot massage, whether administered by a professional masseuse or a loved one, can bring ... of Multiple Specialties in Podiatry (ABMSP) has taken the upcoming Valentine’s Day as ...
(Date:2/5/2016)... CA (PRWEB) , ... February 05, 2016 , ... ... ChildLight Yoga Studio in Dover, NH to direct high-performance kids yoga training. ChildLight Yoga ... Hampshire’s seacoast, just one hour from Boston. , ChildLight Yoga Studio founder Lisa Flynn ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Give To ... users to search for and donate to Give To Cure’s campaign that is crowdfunding ... that lets users make and share payments through a smart device. In 2015 alone, ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Dr. Justin Scott ... their 2nd Annual No Cost Dental Day to individuals in need. The event is ... of this No Cost Dental Day is to provide dental care to community members ...
Breaking Medicine News(10 mins):